Dyne Therapeutics (DYN) Insider Jason Rhodes Sells $2M of Stock

Jason Rhodes Sells More Shares of Dyne Therapeutics

Jason Rhodes sold 95,900 shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) on June 24, 2026. The transaction took place at an average price of $21.02, reaching a total value of $2,015,818.00. This planned move follows a string of earlier disposals by Rhodes and other corporate insiders at the biotech firm.

Inside the Recent Insider Transactions

The June 24 trade fits into a wider pattern of scheduled sales executed under pre-arranged trading plans by key figures at the company. Earlier in June, Rhodes completed several other sales, including a transaction on June 26 involving 309,268 shares valued at $6,581,223.04, a sale of 147,760 shares on June 23 valued at $3,122,168.80, and a smaller disposal of 24,100 shares on June 25 valued at $508,510.00. Additional insider activity during the same period included CFO Erick Lucera parting with 2,362 shares for $48,113.94 on June 25, alongside multiple sales by Dirk Kersten earlier in the month.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics changed hands around $20.94 recently, positioning the company with a market capitalization near $3.20 billion. The stock trades above its 200-day moving average of $19.78, though it sits under its 50-day moving average of $23.85. Over the past year, the equity has moved between a low of $11.92 and a high of $27.30.

Wall Street Analyst Views

Analyst firms have stayed active with coverage, updating targets across the board in late summer and early fall. On September 30, 2026, Chardan Capital maintained its Buy rating with a $38.00 price target, while HC Wainwright & Co. kept a Buy rating and adjusted its target to $32.00 from $50.00. Piper Sandler reiterated an Overweight rating with a $47.00 target on September 29, 2026. Earlier in September, Morgan Stanley maintained an Overweight rating with a $36.00 target, JP Morgan moved to an Underweight rating with a $10.00 target, RBC Capital kept an Outperform rating with a $30.00 target, and Baird maintained an Outperform rating with a $26.00 target. Overall, the stock holds a consensus strong buy rating backed by 15 analyst opinions.

What Dyne Therapeutics Does

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts, focusing on treatments for neuromuscular diseases. The firm applies its proprietary delivery platform to build a pipeline addressing conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease.

What's Ahead for Dyne Therapeutics, Inc.

Market participants will monitor further Form 4 filings to track whether insiders continue adjusting their holdings. The company's next scheduled financial update is set for November 5, 2026, when management reports earnings for the period.